- Welcome and Introduction
- Immune Checkpoint Inhibitors in the Management of Metastatic TNBC
- Antibody-Drug Conjugates Targeting Cell Surface Receptors and Other Immune-Based Approaches
- Audience Q&A
Nadia Harbeck, MD, PhD
Head, Breast Center
University of Munich (LMU)
Ian E. Krop, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Associate Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging immune checkpoint inhibitor–based therapies for treatment of triple-negative breast cancer.
This program is intended for global physicians and other healthcare professionals who care for patients with triple-negative breast cancer.
Upon completion of this activity, participants should be able to:
- Plan individualized first-line treatment with immune checkpoint inhibitor–based therapy for individual patients with locally advanced or metastatic triple-negative breast cancer
- Apply clinical evidence and expert recommendations using antibody–drug conjugates for patients with progressive triple-negative breast cancer after 1 or more previous lines of therapy
- Manage specific treatment-related complications associated with the use of immune-based therapies and combinations in patients with breast cancer
- Appraise ongoing clinical trials assessing new immune-based approaches for appropriate patients with no biomarkers or those with HER2-low or HER3-high triple-negative breast cancer
- Evaluate recently presented data as part of ESMO Breast 2021
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.